Zobrazeno 1 - 10
of 46
pro vyhledávání: '"Nizar N. Tannir"'
Autor:
Xiaoping Su, Xiaofan Lu, Sehrish Khan Bazai, Eva Compérat, Roger Mouawad, Hui Yao, Morgan Rouprêt, Jean-Philippe Spano, David Khayat, Irwin Davidson, Nizar N. Tannir, Fangrong Yan, Gabriel G. Malouf
Publikováno v:
Genome Biology, Vol 22, Iss 1, Pp 1-25 (2021)
Abstract Background Crosstalk between genetic, epigenetic, and immune alterations in upper tract urothelial carcinomas and their role in shaping muscle invasiveness and patient outcome are poorly understood. Results We perform an integrative genome-
Externí odkaz:
https://doaj.org/article/748cdc358889450e961ea858eedaa339
Autor:
Nizar N. Tannir, Hui Yao, Morgan Rouprêt, Roger Mouawad, David Khayat, Eva Compérat, Irwin Davidson, Jean Philippe Spano, Fangrong Yan, Sehrish Khan Bazai, Xiaoping Su, Xiaofan Lu, Gabriel G. Malouf
Publikováno v:
Genome Biology, Vol 22, Iss 1, Pp 1-25 (2021)
Genome Biology
Genome Biology, BioMed Central, 2021, 22 (1), ⟨10.1186/s13059-020-02230-w⟩
Genome Biology, 2021, 22 (1), ⟨10.1186/s13059-020-02230-w⟩
Genome Biology
Genome Biology, BioMed Central, 2021, 22 (1), ⟨10.1186/s13059-020-02230-w⟩
Genome Biology, 2021, 22 (1), ⟨10.1186/s13059-020-02230-w⟩
Background Crosstalk between genetic, epigenetic, and immune alterations in upper tract urothelial carcinomas and their role in shaping muscle invasiveness and patient outcome are poorly understood. Results We perform an integrative genome- and methy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a6a0f23cf58a96f940692cbc3cc33aae
https://doaj.org/article/748cdc358889450e961ea858eedaa339
https://doaj.org/article/748cdc358889450e961ea858eedaa339
Autor:
Pant S; University of Texas MD Anderson Cancer Center, Houston, TX, USA., Cho BC; Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea., Kyriakopoulos CE; University of Wisconsin Carbone Cancer Center, Madison, WI, USA., Spira A; Virginia Cancer Specialists, Fairfax, VA, USA., Tannir N; University of Texas MD Anderson Cancer Center, Houston, TX, USA., Werner TL; Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA., Yan X; Mirati Therapeutics Inc., San Diego, CA, USA., Neuteboom S; Mirati Therapeutics Inc., San Diego, CA, USA., Chao R; Mirati Therapeutics Inc., San Diego, CA, USA., Goel S; Montefiore Medical Center, Bronx, NY, USA. sanjay.goel@rutgers.edu.; Rutgers Cancer Institute, New Brunswick, NJ, USA. sanjay.goel@rutgers.edu.
Publikováno v:
Investigational new drugs [Invest New Drugs] 2024 Oct; Vol. 42 (5), pp. 547-558. Date of Electronic Publication: 2024 Aug 21.
Autor:
Shanker MD; The University of Texas MD Anderson Cancer Centre Houston Texas USA.; The University of Queensland Brisbane Australia., Yu ZH; The University of Texas MD Anderson Cancer Centre Houston Texas USA., Yang J; The University of Texas MD Anderson Cancer Centre Houston Texas USA., Matin S; The University of Texas MD Anderson Cancer Centre Houston Texas USA., Campbell MT; The University of Texas MD Anderson Cancer Centre Houston Texas USA., Msaouel P; The University of Texas MD Anderson Cancer Centre Houston Texas USA., Tannir N; The University of Texas MD Anderson Cancer Centre Houston Texas USA., Prajapati S; The University of Texas MD Anderson Cancer Centre Houston Texas USA., Ding Y; The University of Texas MD Anderson Cancer Centre Houston Texas USA., Lee B; The University of Texas MD Anderson Cancer Centre Houston Texas USA., Sobremonte A; The University of Texas MD Anderson Cancer Centre Houston Texas USA., Tang C; The University of Texas MD Anderson Cancer Centre Houston Texas USA.
Publikováno v:
BJUI compass [BJUI Compass] 2024 Aug 30; Vol. 5 (10), pp. 913-915. Date of Electronic Publication: 2024 Aug 30 (Print Publication: 2024).
Autor:
McQuade JL; Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston., Hammers H; Kidney Cancer Program, Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas., Furberg H; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York., Engert A; German Hodgkin Study Group (GHSG), University Hospital of Cologne, Cologne, Germany., André T; Department of Medical Oncology, Sorbonne University and Saint-Antoine Hospital, Paris, France., Blumenschein G Jr; Department of Thoracic Medical Oncology, University of Texas MD Anderson Cancer Center, Houston., Tannir N; Department of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, Houston., Baron A; Division of Hematology Oncology, California Pacific Medical Center, San Francisco., Larkin J; Department of Medical Oncology, The Royal Marsden Hospital NHS Foundation Trust, London, United Kingdom., El-Khoueiry A; Department of Medicine, USC Norris Comprehensive Cancer Center, Los Angeles, California., Carbone DP; Department of Internal Medicine, Division of Medical Oncology, Ohio State University, Columbus., Thomas JM; Bristol Myers Squibb, Princeton, New Jersey., Hennicken D; Bristol Myers Squibb, Princeton, New Jersey., Coffey M; Bristol Myers Squibb, Princeton, New Jersey., Motzer RJ; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Publikováno v:
JAMA oncology [JAMA Oncol] 2023 Jan 01; Vol. 9 (1), pp. 102-111.
Autor:
Siddiqui BA; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Gheeya JS; Department of Internal Medicine, The University of Texas Health Science Center at Houston, Houston, Texas, USA., Goswamy R; Department of Internal Medicine, The University of Texas Health Science Center at Houston, Houston, Texas, USA., Bathala TK; Department of Abdominal Imaging, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Surasi DS; Department of Nuclear Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Gao J; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Shah A; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Campbell MT; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Msaouel P; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Goswami S; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Wang J; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Zurita AJ; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Jonasch E; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Corn PG; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Aparicio AM; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Siefker-Radtke AO; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Sharma P; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Subudhi SK; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Tannir N; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA ntannir@mdanderson.org.
Publikováno v:
Journal for immunotherapy of cancer [J Immunother Cancer] 2021 Jul; Vol. 9 (7).
Autor:
Piha-Paul SA; Department of Investigational Cancer Therapeutics (A Phase I Clinical Trials Program), University of Texas MD Anderson Cancer Center, Houston, TX, USA., Dumbrava EE; Department of Investigational Cancer Therapeutics (A Phase I Clinical Trials Program), University of Texas MD Anderson Cancer Center, Houston, TX, USA., Nair BC; Department of Investigational Cancer Therapeutics (A Phase I Clinical Trials Program), University of Texas MD Anderson Cancer Center, Houston, TX, USA., Xiong W; Department of Investigational Cancer Therapeutics (A Phase I Clinical Trials Program), University of Texas MD Anderson Cancer Center, Houston, TX, USA., Xu L; Department of Investigational Cancer Therapeutics (A Phase I Clinical Trials Program), University of Texas MD Anderson Cancer Center, Houston, TX, USA., Mostorino R; Department of Investigational Cancer Therapeutics (A Phase I Clinical Trials Program), University of Texas MD Anderson Cancer Center, Houston, TX, USA., Subbiah V; Department of Investigational Cancer Therapeutics (A Phase I Clinical Trials Program), University of Texas MD Anderson Cancer Center, Houston, TX, USA., Tannir N; Department of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Fu S; Department of Investigational Cancer Therapeutics (A Phase I Clinical Trials Program), University of Texas MD Anderson Cancer Center, Houston, TX, USA., Naing A; Department of Investigational Cancer Therapeutics (A Phase I Clinical Trials Program), University of Texas MD Anderson Cancer Center, Houston, TX, USA., Janku F; Department of Investigational Cancer Therapeutics (A Phase I Clinical Trials Program), University of Texas MD Anderson Cancer Center, Houston, TX, USA., Karp DD; Department of Investigational Cancer Therapeutics (A Phase I Clinical Trials Program), University of Texas MD Anderson Cancer Center, Houston, TX, USA., Patel S; Department of Sarcoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Daw NC; Department of Pediatrics, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Hong D; Department of Investigational Cancer Therapeutics (A Phase I Clinical Trials Program), University of Texas MD Anderson Cancer Center, Houston, TX, USA., Meric-Bernstam F; Department of Investigational Cancer Therapeutics (A Phase I Clinical Trials Program), University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Department of Breast Surgical Oncology, University of Texas, MD Anderson Cancer Center, Houston, TX, USA.; The Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Zinner R; Department of Medical Oncology, Thomas Jefferson University Hospital, Philadelphia, PA, USA.
Publikováno v:
OncoTargets and therapy [Onco Targets Ther] 2021 May 07; Vol. 14, pp. 3037-3049. Date of Electronic Publication: 2021 May 07 (Print Publication: 2021).
Autor:
Laccetti AL; Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Garmezy B; Department of Cancer Medicine, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA., Xiao L; Department of Genitourinary Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA., Economides M; Department of Internal Medicine, McGovern Medical School at UTHealth, Houston, TX, USA., Venkatesan A; Department of Radiology, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA., Gao J; Department of Genitourinary Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA., Jonasch E; Department of Genitourinary Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA., Corn P; Department of Cancer Medicine, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA., Zurita-Saavedra A; Department of Cancer Medicine, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA., Brown LC; Division of Medical Oncology, Department of Medicine, Duke University, Durham, NC, USA., Kao C; Division of Medical Oncology, Department of Medicine, Duke University, Durham, NC, USA., Kinsey EN; Division of Medical Oncology, Department of Medicine, Duke University, Durham, NC, USA., Gupta RT; Duke Cancer Institute Center for Prostate and Urologic Cancers, Durham, NC, USA.; Department of Radiology, Duke University, Durham, NC, USA., Harrison MR; Division of Medical Oncology, Department of Medicine, Duke University, Durham, NC, USA.; Duke Cancer Institute Center for Prostate and Urologic Cancers, Durham, NC, USA., Armstrong AJ; Division of Medical Oncology, Department of Medicine, Duke University, Durham, NC, USA.; Duke Cancer Institute Center for Prostate and Urologic Cancers, Durham, NC, USA., George DJ; Division of Medical Oncology, Department of Medicine, Duke University, Durham, NC, USA.; Duke Cancer Institute Center for Prostate and Urologic Cancers, Durham, NC, USA., Tannir N; Department of Genitourinary Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA., Msaouel P; Department of Genitourinary Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA., Shah A; Department of Genitourinary Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA., Zhang T; Division of Medical Oncology, Department of Medicine, Duke University, Durham, NC, USA.; Duke Cancer Institute Center for Prostate and Urologic Cancers, Durham, NC, USA., Campbell MT; Department of Genitourinary Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.
Publikováno v:
Cancer medicine [Cancer Med] 2021 Apr; Vol. 10 (7), pp. 2341-2349. Date of Electronic Publication: 2021 Mar 01.
Autor:
Choueiri TK; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Atkins MB; Department of Oncology, Georgetown Lombardi Comprehensive Cancer Center, Washington, DC., Bakouny Z; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Carlo MI; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Drake CG; Department of Medicine, Columbia University Medical Center, New York, NY, USA., Jonasch E; Department of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Kapur P; Department of Pathology, University of Texas Southwestern Medical Center, Dallas, TX, USA., Lewis B; KidneyCAN, Philadelphia, PA, USA., Linehan WM; Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Mitchell MJ; Department of Bioengineering, University of Pennsylvania, Philadelphia, PA, USA., Pal SK; Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, CA, USA., Pels K; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Poteat S; KidneyCAN, Philadelphia, PA, USA., Rathmell WK; Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA., Rini BI; Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA., Signoretti S; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA., Tannir N; Department of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Uzzo R; Department of Surgical Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA., Wood CG; Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Hammers HJ; Department of Pathology, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Publikováno v:
Journal of the National Cancer Institute [J Natl Cancer Inst] 2021 Mar 01; Vol. 113 (3), pp. 234-243.
Autor:
Naing A; Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA anaing@mdanderson.org., Meric-Bernstam F; Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Stephen B; Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Karp DD; Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Hajjar J; Section of Immunology, Allergy and Rheumatology, Texas Children's Hospital, Baylor College of Medicine, Houston, Texas, USA., Rodon Ahnert J; Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Piha-Paul SA; Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Colen RR; Cancer Systems Imaging, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Jimenez C; Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Raghav KP; Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Ferrarotto R; Thoracic/Head & Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Tu SM; Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Campbell M; Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Wang L; Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Sabir SH; Interventional Radiology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Tapia C; Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Bernatchez C; Melanoma Medical Oncology-Research, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Frumovitz M; Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Tannir N; Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Ravi V; Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Khan S; Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Painter JM; Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Abonofal A; Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Gong J; Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Alshawa A; Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., McQuinn LM; Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Xu M; Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Ahmed S; Cancer Systems Imaging, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Subbiah V; Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Hong DS; Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Pant S; Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Yap TA; Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Tsimberidou AM; Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Dumbrava EEI; Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Janku F; Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Fu S; Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Simon RM; R Simon Consulting, Potomac, Maryland, USA., Hess KR; Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Varadhachary GR; Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Habra MA; Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Publikováno v:
Journal for immunotherapy of cancer [J Immunother Cancer] 2020 Mar; Vol. 8 (1).